Eli Lilly and Company is to invest $3 billion into an expansion of its Kenosha County, Wisconsin, manufacturing facility, acquired by the company earlier this year.

The investment will extend the company’s global parenteral (injectable) product manufacturing network, helping to meet the growing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas. The acquisition, expansion, and additional purchases of land and the adjacent warehouse bring Lilly’s total planned investment in Wisconsin to a reported $4 billion. The expanded facility will focus on manufacturing injectable medicines, device assembly and packaging for medicines across multiple therapeutic areas. Lilly intends to leverage advanced automation, including guided vehicles, robotics and production equipment, to accelerate medicine production.